An article from MedPage Today referenced a study published in the March 2024 issue of AJMC. The study, “The Extent and Growth of Prior Authorization in Medicare Advantage,” found that about 3 in 4 enrollees in Medicare Advantage had a plan that required prior authorization, with some area-level demographic and provider market characteristics associated with prior authorization requirements.
An article from UPI referenced an FDA approval news item published on AJMC.com, the website of AJMC. The article, “FDA Approves Marstacimab, First Weekly Sub-Q Option for Hemophilia B,” featured an FDA decision on marstacimab, which reduced annualized bleeding rates by 35% compared with prophylaxis and 92% compared with on-demand treatment in patients with hemophilia B.
An article from Pharmacy Times referenced an article published by AJMC®’s sister site, The Center for Biosimilars. The article, “Phase 3 Trials Find Subcutaneous Infliximab CT-P13 Superior to Placebo in IBD,” reported on the phase 3 results for infliximab in patients living with inflammatory bowel disease, with 62% of those receiving CT-P13 achieving clinical remission.